
Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …

Pfizer’s kidney cancer pill Inlyta has been recommended for use by a European committee. The Committee for Medicinal Products for …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

